Thermo Fisher Scientific Inc. $TMO Position Lowered by Sterling Investment Counsel LLC

Key Points

• Sterling Investment Counsel LLC reduced its stake in Thermo Fisher Scientific by 70.3% during the second quarter, bringing its holdings to 639 shares valued at $259,000.
• Thermo Fisher's latest quarterly earnings showed $5.36 EPS, exceeding analysts' expectations of $5.22 with a revenue of $10.86 billion, up 2.9% year-over-year.
• The company recently announced a quarterly dividend of $0.43 per share, with a dividend yield of 0.3% and a payout ratio of 9.95%.

Sterling Investment Counsel LLC decreased its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 70.3% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 639 shares of the medical research company's stock after selling 1,515 shares during the period. Sterling Investment Counsel LLC's holdings in Thermo Fisher Scientific were worth $259,000 as of its most recent filing with the SEC.

Several other large investors have also modified their holdings of TMO. CBIZ Investment Advisory Services LLC lifted its position in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $30,000. Keystone Global Partners LLC bought a new position in Thermo Fisher Scientific in the first quarter worth about $31,000. DiNuzzo Private Wealth Inc. lifted its holdings in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock worth $31,000 after acquiring an additional 61 shares during the last quarter. Finally, IMA Advisory Services Inc. bought a new position in Thermo Fisher Scientific in the first quarter worth about $35,000. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Price Performance

NYSE TMO opened at $525.07 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $611.49. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. The firm has a market capitalization of $198.27 billion, a PE ratio of 30.37, a P/E/G ratio of 2.88 and a beta of 0.77. The company's 50 day simple moving average is $481.27 and its 200 day simple moving average is $447.60.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The business had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter last year, the business earned $5.37 earnings per share. The business's revenue for the quarter was up 2.9% on a year-over-year basis. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be paid a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 9.95%.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on TMO shares. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a report on Sunday, September 7th. Robert W. Baird raised their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the stock an "outperform" rating in a report on Thursday, July 24th. HSBC reaffirmed a "hold" rating and set a $510.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Finally, Barclays lifted their price target on Thermo Fisher Scientific from $550.00 to $585.00 and gave the company an "overweight" rating in a report on Thursday. Fifteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $585.37.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the transaction, the executive vice president owned 22,367 shares in the company, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $500.96, for a total transaction of $5,009,600.00. Following the completion of the transaction, the chief executive officer owned 115,174 shares in the company, valued at approximately $57,697,567.04. This trade represents a 7.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 30,066 shares of company stock worth $14,182,963 over the last quarter. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.